Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors

Saitō, Tsunemasa; Ohnuma, Kei; Suzuki, Hiroshi; Dang, Nam H.; Hatano, Ryou; Ninomiya, Hiroki; Morimoto, Chikao

doi:10.1016/j.diabres.2013.07.010

Cited by 26 publications

(24 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although they are not first‐line agents because of expense and modest efficacy, they may be attractive to some older adults with type 2 diabetes mellitus because they are once‐daily oral agents, do not cause hypoglycemia, and are weight neutral. Two case–control studies suggest an association between these agents and severe joint pain, with joint pain resolving with withdrawal of the agent in most cases . The FDA issued a warning in 2015 about the risk of severe and disabling joint pain and recommended that clinicians stop these agents in individuals complaining of joint pain…”

Section: Important Side Effects Of Drugs Commonly Prescribed In Primamentioning

confidence: 99%

Common Drug Side Effects and Drug‐Drug Interactions in Elderly Adults in Primary Care

Merel

Paauw

2017

J American Geriatrics Society

View full text Add to dashboard Cite

Prescribing medications, recognizing and managing medication side effects and drug interactions, and avoiding polypharmacy are all essential skills in the care of older adults in primary care. Important side effects of medications commonly prescribed in older adults (statins, proton pump inhibitors, trimethoprim-sulfamethoxazole and fluoroquinolone antibiotics, zolpidem, nonsteroidal antiinflammatory drugs, selective serotonin reuptake inhibitors, dipeptidyl peptidase 4 inhibitors) were reviewed. Important drug interactions with four agents or classes (statins, warfarin, factor Xa inhibitors, and calcium channel blockers) are discussed.

show abstract

Section: Important Side Effects Of Drugs Commonly Prescribed In Primamentioning

confidence: 99%

Common Drug Side Effects and Drug‐Drug Interactions in Elderly Adults in Primary Care

Merel

Paauw

2017

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

“…However, the regulatory mechanism of DPP4 and SDF-a in arthritis appears to be somewhat complex and has not yet been elucidated [8,134]. Different results were obtained from clinical and epidemiological studies with anti-diabetic DPP4 inhibitors regarding increased or lower risks of polyarthropathy and autoimmune diseases such as RA in patients with type 2 diabetes mellitus (T2DM) [135,136]. Implementing differential diagnostics of polyarthropathy other than RA, osteoarthritis and crystal-associated arthritis, as well as analysing various cytokines and chemokines, higher incidences of polyarthropathy, were found in patients treated with DPP4 inhibitors.…”

Section: Asthmamentioning

confidence: 98%

“…Intriguingly, the polyarthropathy was associated with reduced levels of SDF-a in plasma from T2DM patients receiving DPP4 inhibitors. Following cessation of DPP4 inhibitors, the clinical symptoms of polyarthropathy resolved within 3 months and the plasma levels of SDF-a were restored [135]. In contrast, the risks of developing an autoimmune disease such as RA seems to be lower upon treatment with DPP4 inhibitors, according to epidemiological studies [136].…”

Section: Asthmamentioning

confidence: 99%

Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins

Wagner¹,

Klemann²,

Stephan

et al. 2016

Clinical and Experimental Immunology

100

107

View full text Add to dashboard Cite

SummaryDipeptidyl peptidase (DPP) 4 (CD26, DPP4) is a multi-functional protein involved in T cell activation by co-stimulation via its association with adenosine deaminase (ADA), caveolin-1, CARMA-1, CD45, mannose-6-phosphate/insulin growth factor-II receptor (M6P/IGFII-R) and C-X-C motif receptor 4 (CXC-R4). The proline-specific dipeptidyl peptidase also modulates the bioactivity of several chemokines. However, a number of enzymes displaying either DPP4-like activities or representing structural homologues have been discovered in the past two decades and are referred to as DPP4 activity and/or structure homologue (DASH) proteins. Apart from DPP4, DASH proteins include fibroblast activation protein alpha (FAP), DPP8, DPP9, DPP4-like protein 1 (DPL1, DPP6, DPPX L, DPPX S), DPP4-like protein 2 (DPL2, DPP10) from the DPP4-gene family S9b and structurally unrelated enzyme DPP2, displaying DPP4-like activity. In contrast, DPP6 and DPP10 lack enzymatic DPP4-like activity. These DASH proteins play important roles in the immune system involving quiescence (DPP2), proliferation (DPP8/DPP9), antigen-presenting (DPP9), costimulation (DPP4), T cell activation (DPP4), signal transduction (DPP4, DPP8 and DPP9), differentiation (DPP4, DPP8) and tissue remodelling (DPP4, FAP). Thus, they are involved in many pathophysiological processes and have therefore been proposed for potential biomarkers or even drug targets in various cancers (DPP4 and FAP) and inflammatory diseases (DPP4, DPP8/DPP9). However, they also pose the challenge of drug selectivity concerning other DASH members for better efficacy and/or avoidance of unwanted side effects. Therefore, this review unravels the complex roles of DASH proteins in immunology.Keywords: antigen presentation/processing, CD26, co-stimulation, DPP4 activity and/or structure homologue proteins (DASH), signal transductionThe dipeptidyl peptidase (DPP)4 family of DPP4 activity and/or structure homologue (DASH) proteins Within the last two decades a number of enzymes have been discovered to also display DPP4-like activity or are structural homologues to DPP4. These enzymes/proteins are referred to as DPP4 activity and/or structure homologue (DASH) proteins, and can be grouped into the DPP4 gene family and non-related DPP4-like enzymes. Except for DPL1 and DPL2, all members display DPP4-like activity with neutral to basic pH optima and similar inhibition profiles [6,7]. DPP4 (CD26). DPP4 (CD26) is the best-known DASH protein and has been described in detail elsewhere [7][8][9].

show abstract

“…This could explain the manifestation of e.g. polyarthropathy [21] and several case-report observations of the manifestation of rheumatoid arthritis [22,23] development of allergic rhinitis [24] and bullous pemphigoid [25] in certain predisposed individuals in conjunction with gliptin use.…”

Section: Discussionmentioning

confidence: 97%

The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus

Sromova

Bušek

Posová

et al. 2016

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors

Cited by 26 publications

References 18 publications

Common Drug Side Effects and Drug‐Drug Interactions in Elderly Adults in Primary Care

Common Drug Side Effects and Drug‐Drug Interactions in Elderly Adults in Primary Care

Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins

The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus

Contact Info

Product

Resources

About